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Diﬀerentiated thyroid cancer (DTC) is the second most common cancer in pregnancy. Its management is a challenge for both
doctors and patients, and the best timing for surgery is unclear. A systematic review evaluating the prognosis of DTC in pregnant
patients was conducted. After reviewing 401 unique citations and 54 full texts, 4 studies that compared the prognosis of patients
with DTC related to pregnancy (DTC diagnosed during pregnancy or within 12 months after childbirth) or not were included. In
two studies the primary outcome was overall survival, in one study the primary outcomes were recurrent disease and death related
to thyroid cancer, and in one study the primary outcome was recurrent or persistent disease. In the ﬁrst two studies, there was no
diﬀerence in overall survival in patients with pregnancy-related DTC, when compared with matched controls; in one study, there
was no diﬀerence in death caused by DTC nor recurrence in DTC related to pregnancy. Nevertheless, in a recent retrospective
study, a higher rate of recurrent or persistent DTC was observed in patients with DTC related to pregnancy. There are not many
studies on which to base treatment decisions in pregnant patients with DTC.
1.Introduction
Thyroid cancer currently ranks tenth in incidence among
solidorganmalignancies.Themajorityofthyroidcancersare
classiﬁedaspapillary(88%)orfollicular(9%);togetherthese
two histological types are grouped as diﬀerentiated thyroid
cancers (DTC) [5]. While the annual rate of cancer incidence
is decreasing, there has been a 2.4-fold increase in thyroid
cancer from 1973 to 2002 [6].
DTC occurs more commonly in women of child-bearing
age with an incidence of 14 per 100,000 live births and
representsthesecondmostfrequenttumordiagnosedduring
pregnancy only behind breast cancer [7, 8]. As DTC is com-
monly found during pregnancy or in the early postpartum
period [9], it is possible that physiological changes associ-
ated with it, as high levels of estrogen, human chorionic
gonadotropin (hCG) and/or others, could create a favorable
environment to tumor development and growth. Maternal
thyroid gland secretes more thyroid hormone during early
pregnancy in response to the thyrotropic activity of hCG
that overrides the operation of the hypothalamic-pituitary-
thyroid feedback system. This could partially explain an
increase in the size of preexisting thyroid nodules as well as
new thyroid nodule formation in pregnancy [10–15].
The best treatment option for thyroid cancer in pregnant
women or in the early postpartum period should be based
on evidence, so the aim of this paper was to evaluate whether
the prognosis of DTC associated with pregnancy is similar or
not to DTC in nonpregnant women.
2. Methods
2.1. Search Strategy. This literature search was conducted in
the PubMed, Cochrane, and Scopus databases, combining
the MESH terms: thyroid neoplasms and pregnancy. All
studies in English until February 2011 were included.2 Journal of Thyroid Research
54 potentially relevant full-text studies
reviewed by two reviewers
347 studies excluded since not
relevant or met exclusion criteria
14 excluded since DTC was not
diagnosed in pregnant patients or in the
ﬁrst 12months postpartum
10 excluded since no reporting of
outcomes
3 excluded since review
3 excluded since no control group
4 unique studies
included
(consensus)
17 excluded since case series ≤5
patients
398 abstracts obtained from electronic search +
3references from other sources
= total 401 unique references
3 excluded since nonthyroid cancer
Figure 1: Process of study selection for the systematic review.
2.2. Inclusion and Exclusion Criteria for Studies. To be
included in this review the original article should describe
the comparison between the outcomes in patients diagnosed
with DTC during pregnancy or in the ﬁrst 12 months
postpartum (DTC related to pregnancy), with a control
group comprising women of child-bearing age, diagnosed
with DTC when nonpregnant or at least 12 months after
delivery.
Patients should have no prior exposure to radiation or
previous malignancies.
2.3. Selection of Studies for Inclusion. All citations and
abstracts identiﬁed by the electronic search were reviewed by
two independent reviewers. Any abstract identiﬁed as rele-
vant was analyzed as a full text. Other sources of obtaining
papers were used, as cross-referencing texts reviewed.
3. Results andDiscussion
After reviewing 398 abstracts from the electronic search and
3 summaries obtained by manual search, 54 articles were
reviewed in full-text form. However, after analysis of these
studies, several were excluded, for the following reasons:
DTC did not occur during pregnancy, there was no control
group, therewasno reporting ofoutcomes,or theydescribed
small case series, so only four studies were included in this
paper, as shown in Figure 1 [1–4]. The characteristics of
the studies and the outcomes are described, respectively, in
Tables 1 and 2.
There are only a few studies about outcomes of DTC
related to pregnancy. As DTC has a good prognosis, the
number of patients studied should be large, and the followup
should be very long to detect any diﬀerence in survival
or even recurrence. Most recurrences of DTC occur within
the ﬁrst ﬁve years after initial treatment, but recurrences
may occur many years or even decades later, particularly
in patients with papillary cancer [16, 17]. In addition to
this, decisions about cancer treatment during pregnancy are
associated with ethical conﬂicts between the best option for
the mother and for the fetus [18, 19]. The management of
pregnant women with cancer should consider the maternal-
fetal risk related to treatment, as well as the possibility
of tumor progression for postponing treatment or for the
tumor being related to pregnancy. During this study we
could observe that there is little published data comparing
outcomes in patients with DTC related to pregnancy or not.
No randomized controlled trial was available.
In the study of Moosa and Mazzaferri there was no
impact from pregnancy in DTC-related death [3]; in the
studies of Yasmeen et al. and Herzon et al. overall survival
was not aﬀected by DTC [2, 4]; when evaluating if the
timing of surgical treatment, during pregnancy or after
birth, aﬀected the prognosis of patients with DTC detected
during pregnancy, Moosa and Mazzaferri and Yasmeen et al.
[2, 3] have not shown diﬀerences in recurrence rates and,
respectively, in DTC-related death and overall survival. Such
ﬁndings, however, are not in agreement with the study pub-
lished by Vannucchi et al. They found a strong association
of DTC in pregnant women with recurrence or persistence
of cancer (60% in pregnant women (group 2) versus 4.2%
in women with DTC diagnosed 1 year after delivery (group
1) versus 13.1% in nulliparous patients when diagnosed with
DTC (group 3)). After a stepwise logistic regression analysis
entering the following variables: extrathyroidal extension,Journal of Thyroid Research 3
Table 1: Characteristics of the included studies.
Study Study design Study population Control group description Followup (median)
Vannucchi et al.,
2010 [1]
Retrospective cohort in a
single institution—1995–2006
14 women (one aﬀected
twice), age 32.2 ±6.4yr ,
DTC diagnosed during
pregnancy (G2)
47 women, age
36.1 ±3.6yr ,DTC
diagnosed at least one year
after delivery (G1), and 61
nulliparous women when
diagnosed with DTC, age
34.1 ±6.2yr ,(G3)
G1: 68.2 months
G2: 60.1 months
G3: 64.7 months
Yasmeen et al.,
2005 [2]
Population-based case control
study—California 1991–1999
595 pregnant women with
DTC, 129 diagnosed during
pregnancy and 466
diagnosed within 12
months postpartum
2270 age-matched
nonpregnant women with
DTC
Not reported
Moosa and
Mazzaferri, 1997
[3]
Case control study—United
States Air Force registry
61 pregnant women with
DTC, age 26.0 ±5.9yr
528 age-matched
nonpregnant women with
DTC, age 26.3 ±5.9yr
22.4yr in study
population and
19.5yr in control
group
Herzon et al., 1994
[4]
Case control study—New
Mexico Registry 1970–1991
22 pregnant women with
DTC, age 18–46yr
465 women with DTC in
the same database, age
18–46yr
6m o n t h st o2 0
years reported for
study population
Age (years) is expressed as mean + SD; DTC: diﬀerentiated thyroid cancer; G: group.
lymph-node metastases, radioiodine treatment, pregnant
or not pregnant status at diagnosis, histotype, and tumor
size ≤2o r>2cm, pregnancy was found to be the most
signiﬁcant predictor for disease recurrence or persistence
[1]. As the outcomes and the methodology employed in
each study were diﬀerent, it was not possible to compare
their results and to combine the data in a meta-analysis.
In the studies of Yasmeen et al. and Herzon et al., the
o v e r a l ls u rv i v a lw a st h em a i no u t c o m e[ 2, 4], while the study
of Moosa and Mazzaferri had death related to DTC and
recurrence, evaluated by biopsy or by 131I uptake in distant
sites, as primary outcomes [3], and the more recent study of
Vannucchi et al. evaluated persistent/recurrent DTC through
more sensible tests such as Tg basal levels and Tg response
to rhTSH [1]. Such methods were not used in the study of
Moosa and Mazzaferri [3], which could explain some of the
discrepancies among them.
In the study of Vannucchi et al. more patients from
the pregnant women with DTC had follicular histotype.
However, this factor does not seem to explain the worse
outcome which has been found on the group of patients with
DTCassociatedtopregnancy,sincetwoofthreepatientswith
follicular histology remained in remission [1].
Two studies reported diﬀerences among clinical presen-
tation between pregnant and nonpregnant women [1, 3]. In
the study of Moosa and Mazzaferri, fewer pregnant patients
showedsymptomsassociatedtothyroidnodules(74%versus
43%, P<0.01) [3]. On the other hand, in the study
of Vannucchi et al. DTC was less commonly an incidental
ﬁnding in pregnant patients, probably indicating that these
patients had more aggressive disease [1].
A very interesting molecular datum was described by
Vannucchi et al. The expression of the estrogen receptor
alfa through immunohistochemical analysis was higher in
group 2 patients, as compared to groups 1 and 3 [1]. As
estrogen probably increases proliferative activity of thyroid
follicular cells [20], this hormone could be implicated in a
more aggressive pattern of DTC diagnosed in pregnancy.
Other important factor found in this paper refers to the
time of followup of the studies. The mean median followup
ranged from four to twenty-three years. Considering that
DTC is a disease with low lethality and the followup was not
very long, it is possible that the full impact of DTC on the
patients survival was not evident.
The treatment of choice for both pregnant and nonpreg-
nant patients was thyroidectomy. The central lymphadenec-
tomy (VI-VII levels) was performed on all patients in the
cohort described by Vannucchi et al. [1], and, according to
clinical judgment, in the other studies [2–4]. There seemed
tobenodiﬀerenceontheoutcomeofDTCduringpregnancy
whether the surgery took place at the second trimester of
pregnancy or after childbirth [2–4]. In contrast to these ﬁnd-
ings, Kuy et al. compared the risk of thyroid and parathyroid
surgerycomplicationsinpregnantandnonpregnantwomen,
paired by age, in a retrospective cross-sectional study. A total
of 201 pregnant women and 31155 nonpregnant women
were included; among the 201 pregnant women, 45.8%
have undergone surgery due to thyroid cancer, the others
hadbenignthyroidandparathyroiddiseases.Thyroidectomy
during pregnancy was associated with an increased surgical
complication rate in both malignant (21% to 8%) and
benign diseases (27% to 14%), as well as higher endocrine
complication rates (15.9% to 8.2%) and treatment costs
($6873 versus $5963) [21].
In summary, there are few studies which give base to the
policies about pregnant patients with DTC. Up to present
time, data obtained through systematic review show con-
ﬂicting results when it comes to observed outcomes in this
population.Thereseemtobeahigherdiseaserecurrenceand
persistence rates in this population when current treatment4 Journal of Thyroid Research
Table 2:Mainoutcomesinpatientswithdiﬀerentiatedthyroidcancer(DTC)diagnosedduringpregnancyorwithin12monthsofchildbirth.
Study Timing of surgery (study
group) Outcomes Main study results Comments and others
outcomes
Vannucchi et al.,
2010 [1]
(i) 11 patients operated
during pregnancy and
(ii) 4 patients operated
after deliveryd
(i) Persistent or
recurrent disease
detected by highly
sensitive Tg and rhTSH
(ii) ERα tumor
expression by IHC
(i) ↑Persistent/recurrent
disease in G2 versus G1 and
G3 (60% versus 4.2% and
13.1%)a
(ii) ↑ERα tumor expression
in G2 versus G1 and G3
(87.5% versus 31% and
0%)b
(i) PTC more frequent in
G1 and G3 versus G2
(97.8% and 98.3% versus
80%)c
(ii) DTC was an incidental
ﬁnding more frequently in
G1 and G3
(iii) More sensitive
methods for detecting
recurrence were used in
this study when compared
with others
(iv) Conclusion: pregnancy
has a negative impact on
the outcome of DTC
Yasmeen et al.,
2005 [2]
(i) 96 patients operated
during pregnancy and
(ii) 27 patients operated
after deliverye
Overall survival
No diﬀerence in survival
between
pregnancy-associated
thyroid cancer and
aged-matched nonpregnant
women with DTC
Persistent/recurrent disease
was not evaluated
Moosa and
Mazzaferri, 1997
[3]
(i) 14 patients operated
during pregnancy and
(ii) 47 patients operated
after delivery
(i) Death
(ii) Recurrence
diagnosed by biopsy, or
by 131I uptake in distant
site
No diﬀerence in cancer
recurrence and death in
study and control groups
(i) Outcomes similar in
patients operated after
delivery and during
pregnancy
(ii) Fewer pregnant patients
showed symptoms
associated with thyroid
nodules when compared
with nonpregnant (74%
versus 43%)b
Herzon et al., 1994
[4]
(i) 6 patients operated
during pregnancy and
(ii) 16 patients operated
after delivery
Overall survival
No diﬀerence in survival
between
pregnancy-associated
thyroid cancer and
aged-matched nonpregnant
women with DTC
PTC: papillary histotype; Tg: serum thyroglobulin; rhTSH: recombinant human TSH; ERα: estrogen receptor alfa; G: group; G1: DTC diagnosed at least one
year after pregnancy, G2: DTC diagnosed during pregnancy, G3: DTC diagnosed in nulliparous women or before pregnancy; aP<0.0001; bP = 0.01; cP<
0.0001; d1 patient was considered twice: she had two tumors in two diﬀerent pregnancies; eIn patients with DTC diagnosed during pregnancy.
response evaluation methods are employed. However, the
impact on overall survival in the long time appears to be
unaltered. There is no evidence to support termination of
pregnancy when the diagnosis of DTC is performed. The
guidelines of the endocrine society for pregnancy-related
DTC recommend thyroidectomy after delivery for patients
with no evidence of advanced disease or without rapid
progression, and thyroidectomy in the second trimester of
pregnancyfortheothers(USPSTFrecommendationlevelB).
Radioactiveiodineshouldonlybegivenafterdeliveryandthe
ending of breastfeeding [22].
Prospective studies should be done to compare the
prognosisofDTCdiagnosedduringpregnancyornot,aswell
as the eﬀects of postponing surgery after childbirth in DTC
diagnosed during pregnancy.
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